Contact
QR code for the current URL

Story Box-ID: 239594

Nanion Technologies GmbH Ganghoferstrasse 70 A 80339 München, Germany https://www.nanion.de
Company logo of Nanion Technologies GmbH
Nanion Technologies GmbH

Nanion opens US-office in New Jersey

(PresseBox) (München, )
Nanion today announces the opening of Nanion Technologies Inc. with headquarters in North Brunswick, NJ, USA. To support the increasing demand of Nanion’s products, and to continue giving premium customer service, Nanion now expands its presence in the American market.

Nanion opens the doors to the US-office in the “Heart of Pharma”, North Brunswick, NJ. Nanion Technologies Inc. has a fully equipped demonstration and service center for North America, supporting the Port-a-Patch and the Patchliner, and from the end of the year, the SyncroPatch 96. Nanion’s demonstration site is located in Chromocell’s newly built laboratory space. Nanion and Chromocell, a leader in the creation of previously inaccessible drug targets, are engaged in a research partnership.

“With the rapidly growing number of American customers, we need to increase our efforts in the North American market which will strengthen our position as a leading provider of sophisticated and high quality ion channel screening devices. Additionally, swift and competent technical support is very important to us and has always been our trademark. To expand and support the sales in the US, our US-office will make it easier for people to visit us and see our platforms in action.” says Dr. Niels Fertig, CEO of Nanion Technologies.

Rodolfo Haedo, General Manager and Chief Application Scientist, recently joined the Nanion team to support the US customers from the headquarters in North Brunswick. Mr. Haedo has extensive electrophysiology background and valuable experience of various automated patch clamp platforms. Rodolfo Haedo was previously employed at Merck, Rahway, NJ where he was member of Merck’s well renowned ion channel group.

“Rodolfo Haedo’s background in automated electrophysiology is impressive and he is a very good fit for Nanion, especially since we now are in the phase of introducing the SyncroPatch 96, our HTS patch clamp platform. We are very happy to welcome him on board and look forward to a very exciting year!” continues Dr. Fertig.

“I am thrilled to join the Nanion team and to support and promote Nanion’s impressive platforms in the American market. The SyncroPatch 96 is a unique platform considering data quality, throughput, cost efficiency and performance. The platform has the highest throughput on the market, given the data quality, and I am convinced it will be a success because of its enabling screening features.” says Rodolfo Haedo.
With the opening of the US-office, Nanion Technologies Inc. will offer its products in US-dollars for the North American customers.

Nanion Technologies GmbH

Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established two highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.
Nanion's instruments use planar patch clamp chips which replace the traditional glass pipette used in the patch clamp technique. Following the successful market introduction of two automated patch clamp devices, the Port-a-Patch (2004) and the Patchliner (2006), Nanion now introduces a massively parallel patch clamp platform, the SyncroPatch 96.

Nanion was nominated in 2007 for Germany's most prestigious innovation award the Deutscher Zukunftspreis (German Future Prize, Federal President's Award for Technology and Innovation).

Contact details Nanion Europe:
Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: info@nanion.de, Web: www.nanion.de

Contact details Nanion USA:
Rodolfo Haedo, Email: info@naniontech.com, Toll free number US/Can: 1-888-9-NANION
685 US Highway One, North Brunswick, 08902 NJ, USA

About Chromocell:
Chromocell is a drug discovery company focused on the identification and development of novel therapeutics against the most complex and challenging drug targets comprising native or multiple subunits.

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.